144 ·Filed Aug 17, 2026

IVVD

Invivyd, Inc.
NEUTRAL
Impact 2/10
Horizonimmediate Processed1mo ago SEC0001193125-26-354033
Form 144 — notice of proposed sale of securities
Actionable Insight • Neutral

This is a routine tax-withholding sale tied to RSU vesting under a pre-existing 10b5-1 plan. No discretionary insider signal. Monitor for any subsequent discretionary Form 4 filings by officers, but this filing alone carries no actionable trading signal.

DirectionNeutral
Confidencehigh
Horizonimmediate
Latest settled — T+20d
IVVD ▼ -5.55% at T+20d
NEUTRAL call ✗ call lost -5.55% · α vs SPY -4.56% · entry $0.8680 → $0.8198
Next anchor: T+60d in 6w
Latest observation: T+29 +45.79% FF3 residual α
Entry anchored
Aug 17, 04:00 PM ET
via 1-min bar
T+1d
+10.54%
call +10.54% · α +10.33%
$0.9595
settled 6w ago
T+5d
+8.15%
call +8.15% · α +8.35%
$0.9387
settled 6w ago
T+20d
-5.55%
call -5.55% · α -4.56%
$0.8198
settled 17d ago
T+60d
—
call — · α —
—
in 6w

Price Chart

Loading chart...

Executive Summary

Invivyd director William E. Duke filed a Form 144 to sell 40,800 shares (estimated value ~$29,413) in a non-discretionary sell-to-cover transaction to satisfy tax obligations upon RSU vesting. The sale is pre-arranged under a Rule 10b5-1 plan and represents a routine equity compensation event, not a discretionary insider sale.

Key Facts

  • Reporting person: William E. Duke, an Officer of Invivyd
  • Proposed sale of 40,800 shares of common stock
  • Estimated aggregate market value: ~$29,413 (based on $0.7209 closing price on Aug 14, 2026)
  • Sale is a non-discretionary 'sell-to-cover' transaction to satisfy tax obligations upon vesting of RSUs
  • Transaction is pre-arranged under a Rule 10b5-1 plan dated Feb 20, 2025
  • Broker: Morgan Stanley Smith Barney LLC Executive Financial Services

Financial Impact

~$29,413 (40,800 shares at $0.7209/share)

dilutioninsider holdings

Risk Factors

  • None from this filing — routine equity compensation event

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
89% bullish (9 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001193125-26-354033
Document: 0001193125-26-354033-index.html0001193125-26-354033
Document: 0001193125-26-354033.txt0001193125-26-354033
15 reports for IVVD
Performance horizon
75% Hit rate 3 of 4 directional calls best @ T+20▲ +35.85%Jul 6, 2026
Filters
Rows
Reports for IVVD — sortable, filterable
TypeNow
Sep 1, 2026
4w ago
8-K
NEUTRAL ★ 6/10
$0.8800 $0.8441▼ −4.08%▼ −5.26%$0.8221 (−6.58%)
Aug 17, 2026
6w ago
144
NEUTRAL ★ 2/10
$0.8680 $0.8198▼ −5.55%▼ −4.56%$0.8221 (−5.29%)
Jul 6, 2026
12w ago
8-K
BEARISH ★ 6/10
$0.8340 $0.5350▲ +35.85%▲ +35.29%$0.8221 (+1.43%)
Jun 16, 2026
15w ago
Press Release
NEUTRAL ★ 5/10
$0.8918 $0.8008▼ −10.20%▼ −10.40%$0.8221 (−7.82%)
Jun 11, 2026
16w ago
Institutional Cluster
MIXED ★ 4/10
$0.8125 $0.8037▼ −1.08%▼ −2.97%$0.8221 (+1.18%)
Jun 9, 2026
16w ago
Press Release
NEUTRAL ★ 4/10
$0.9900 $0.9418▼ −4.87%▼ −6.32%$0.8221 (−16.96%)
Jun 1, 2026
17w ago
Press Release
BULLISH ★ 5/10
$1.22 $0.8724▼ −28.49%▼ −27.19%$0.8221 (−32.61%)
May 14, 2026
20w ago
8-K
MIXED ★ 6/10
$1.16 $0.7700▼ −33.62%▼ −32.76%$0.8221 (−29.13%)
May 14, 2026
20w ago
Press Release
NEUTRAL ★ 5/10
$1.16 $0.7700▼ −33.62%▼ −32.76%$0.8221 (−29.13%)
Apr 9, 2026
25w ago
8-K
NEUTRAL ★ 5/10
$1.78 $1.46▼ −17.98%▼ −25.55%$0.8221 (−53.81%)
Showing 10 of 15

US Market Status

Market Closed — Opens Mon (64h 37m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access